

***CONFIDENTIAL – CONTAINS TRADE SECRETS***

**Attachment A-1: Company Contact Information**

**Company Name:**

**Company Address:**

**Company PI name:**

**Company PI Email:**

**Additional Company Contact Name:**

**Additional Company Contact Email:**

Attachment A-1: Human Subjects

Activities Involving HUMAN SUBJECTS

	Study			Research Entity				Study Site (if more than one study site per study, list one per excel row.)			Exemption		IRB				
	Proposed CARB-X Stage	Type of Human subjects Research	Anticipated Study Start Date. <sup>1</sup> (e.g., Apr 2018 or Q2 2018)	Type of Entity	Entity Name	Entity Address	Entity FWA # <sup>2</sup>	Name	Address	FWA # <sup>3</sup>	Exempt? (i.e., Not Human Subjects Research designation)	If Yes, Exemption #	IRB Name <sup>4</sup> (if record)	Enter FWA of the IRB (if different than Research Entity)	IRB Approval Status	IRB Approval Date (leave blank if pending)	If more than one IRB must approve the research, describe all.
Study 1																	
Study 2																	
Study 3																	
Study 4																	
Study 5																	
Study 6																	
Study 7																	
Study 8																	
Study 9																	

<sup>1</sup> Study Start Date is subject to satisfactory completion of all compliance requirements.

<sup>2</sup> Enter FWA # of the research entity conducting or responsible for the research.

<sup>3</sup> Enter FWA # of each site performing the study, if different from the research entity or more than one study site is being used.

<sup>4</sup> Enter information about the IRB of record. If more than one IRB approval is required, please complete Column 5.

Attachment A-1: Animal Subjects

Activities involving ANIMAL SUBJECTS

Protocol/Study					IACUC Approval		Performance Site			Inter-Institutional Assurance (IIA)		
Protocol Name <i>(Indicate the Protocol the study/studies fall under)</i>	Study Name(s) <i>(Add more rows if required)</i>	Study Species	Proposed CARB-X Stage	Anticipated Study Start Date(s) <sup>1</sup> <i>(e.g., Apr 2018 or Q2 2018)</i>	Status of IACUC Approval Letter <sup>2</sup>	IACUC Approval Date <i>(Leave blank if pending)</i>	Type of Entity	Entity Name	Entity Address	Animal Welfare Assurance # <sup>3</sup> <i>(Domestic or Foreign)</i>	Inter-Institutional Assurance # <sup>4</sup> <i>(Mark "To be requested" until obtained through CARB-X/BU process)</i>	OLAW Approval Date <i>(Leave blank if pending)</i>

<sup>1</sup> Study Start Date is subject to satisfactory completion of all compliance requirements.

<sup>2</sup> An IACUC (or IACUC equivalent) approval letter is required for each protocol. Preliminary or conditional approvals are insufficient.

<sup>3</sup> Enter the OLAW Assurance # for the performance site.

<sup>4</sup> An Inter-Institutional Assurance (IIA) is required for sites/product developers that do not/cannot have their own Assurance and must rely on a CRO or other third party performance site that has an Assurance. The IIA is CARB-X project specific; it can be requested by CARB-X/BU Administration upon a positive JOC funding decision.

<b>Stage</b>	<b>Status</b>	<b>Type of Entity</b>	<b>IACUC Approval</b>		<b>Type of Study</b>
Base	To Be Requested	CRO	Pending	Yes	Clinical Trial
Option	Pending	In-house	Final	No	Biospecimens
	Obtained	Government agency/entity			Other
		Other			